[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-379289-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-379289-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","international-journal-of-clinical-oncology-japan-led-clinical-recommendations-on-immunotherapy-for-dmmr-tumors-third-edition","International Journal of Clinical Oncology - Japan-led clinical recommendations on immunotherapy for dMMR tumors, third edition","","Clinical trials have shown the effectiveness of immune checkpoint inhibitors for mismatch repair-deficient (dMMR) advanced solid tumors, prompting an update of Japanese, multi-society clinical recommendations. The guideline formulates clinical questions for care of dMMR advanced solid tumor patients, then gathers evidence through PubMed and Cochrane searches with manual additions. Systematic reviews are performed per clinical question, with committee voting that balances evidence strength and patient risks/benefits, followed by expert peer review and public comments. The final guideline provides two clinical questions and eight recommendations on when, for whom, and how to test MMR status to select patients likely to benefit from immunotherapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/international-journal-of-clinical-oncology-japan-led-clinical-recommendations-on-immunotherapy-for-dmmr-tumors-third-edition/379289/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/international-journal-of-clinical-oncology-japan-led-clinical-recommendations-on-immunotherapy-for-dmmr-tumors-third-edition/379289.png","ImageObject",300,407,{"name":42,"@type":43},"Pentious","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of the guideline regarding dMMR tumors?","Question",{"text":63,"@type":64},"To propose recommendations for performing MMR testing properly and to select patients likely to benefit from immunotherapy using immune checkpoint inhibitors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were clinical questions and evidence collected for the recommendations?",{"text":68,"@type":64},"Clinical questions were defined for patients with dMMR advanced solid tumors, and relevant publications were searched using PubMed and Cochrane databases, with critical reports added manually.",{"name":70,"@type":61,"acceptedAnswer":71},"How many recommendations does the current guideline include and what do they cover?",{"text":72,"@type":64},"The guideline describes two clinical questions and eight recommendations covering whom, when, and how MMR status should be tested.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},379289,1790572551,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","International Journal of Clinical Oncology (2023) 28:1237–1258  \n[https://doi.org/10.1007/s10147-023-02397-9](https://doi.org/10.1007/s10147-023-02397-9)  \nJapanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology‑led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition  \nSaori Mishima1 · Yoichi Naito1 · Kiwamu Akagi2 · Naomi Hayashi3 · Akira Hirasawa4 · Tomoro Hishiki5 · Ataru Igarashi6 · Masafumi Ikeda1 · Shigenori Kadowaki7 · Hiroaki Kajiyama8 · Motohiro Kato9 · Hirotsugu Kenmotsu10 · Yasuhiro Kodera11 · Keigo Komine12 · Takafumi Koyama13 · Osamu Maeda11 · Mitsuru Miyachi14 · Hiroshi Nishihara15 · Hiroyuki Nishiyama16 · Shouichi Ohga17 · Wataru Okamoto18 ·  \nEiji Oki17 · Shigeru Ono19 · Masashi Sanada20 · Ikuo Sekine16 · Tadao Takano12 · Kayoko Tao13 · Keita Terashima21 · Katsuya Tsuchihara1 · Yasushi Yatabe13 · Takayuki Yoshino1 · Eishi Baba17  \nReceived: 26 March 2023 / Accepted: 28 July 2023 / Published online: 20 August 2023 © The Author(s) 2023  \nAbstract  \nBackground Clinical trials have reported the efficacy of immune checkpoint inhibitors in the treatment of mismatch repairdeficient (dMMR) advanced solid tumors. The accumulated evidence of tumor agnostic agent has been made since PD-1 inhibitor was approved and used in clinical practice. Therefore, we have revised the guideline “Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition”.  \nMethods Clinical questions regarding medical care were formulated for patients with dMMR advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO), Japanese Society of Medical Oncology (JSMO), and Japanese society of pediatric hematology/oncology (JSPHO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and JSPHO and the public comments among all societies’ members were done.  \nResults The current guideline describes two clinical questions and eight recommendations for whom, when, and how MMR status should be tested.  \nConclusion In this guideline, the committee proposed eight recommendations for performing MMR testing properly to select patients who are likely to benefit from immunotherapy.  \nKeywords Advanced solid tumor · Clinical practice guideline · Mismatch repair-deficient (dMMR) · Microsatellite instability-high (MSI-H) · Immunotherapy · PD-1/PD-L1 inhibitor  \nIntroduction  \nCancer treatment has involved a multifaceted assessment that encompasses the pathological diagnosis of the disease and an evaluation of its progression, the benefits and disadvantages of treatment, and the preferences of the patient.  \nExtended author information available on the last page of the article  \nIn diagnosing the disease, identifying the primary tumor and determining the tissue type has yielded important information that has been key to establishing a treatment plan. Recent advances in molecular biology have elucidated a variety of biological characteristics of tumors, resulting in the development and approval of tumor-agnostic drugs that transcend the organic characteristics of the disease. These guidelines have been formulated to enable the examination  \nand treatment involved in tumor-agnostic therapy, rather than the conventional organ-specific treatment, to be smoothly implemented in the clinical setting.  \nThe","cbCaijINq0jqhEGP","https://ap.wps.com/l/cbCaijINq0jqhEGP","pdf",1701768,22,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusion\n# Introduction\n# Materials and methods","[{\"question\":\"What is the purpose of the guideline regarding dMMR tumors?\",\"answer\":\"To propose recommendations for performing MMR testing properly and to select patients likely to benefit from immunotherapy using immune checkpoint inhibitors.\"},{\"question\":\"How were clinical questions and evidence collected for the recommendations?\",\"answer\":\"Clinical questions were defined for patients with dMMR advanced solid tumors, and relevant publications were searched using PubMed and Cochrane databases, with critical reports added manually.\"},{\"question\":\"How many recommendations does the current guideline include and what do they cover?\",\"answer\":\"The guideline describes two clinical questions and eight recommendations covering whom, when, and how MMR status should be tested.\"}]","International Journal of Clinical Oncology - Japan-led clinical recommendations on immunotherapy for dMMR tumors, third edition | PDF",1790234918,55]